Treatment with infliximab restores normal aquaporin 5 distribution in minor salivary glands of patients with Sjögren's syndrome.
Steinfeld
Serge D
SD
Erasme University Hospital Christine Delporte, Brussels, Belgium.
Appelboom
Thierry
T
Delporte
Christine
C
D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D051402:Aquaporin 5; D020346:Aquaporins / Q000378:metabolism*; D001706:Biopsy; D002452:Cell Count; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007150:Immunohistochemistry; D000069285:Infliximab; D008565:Membrane Proteins; D012470:Salivary Glands, Minor / Q000187:drug effects / Q000378:metabolism*; D012859:Sjogren's Syndrome / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology* / Q000627:therapeutic use
C496036:AQP5 protein, human; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D051402:Aquaporin 5; D020346:Aquaporins; D008565:Membrane Proteins; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab